AI

#AI #Drug discovery #Immune cells

AI-generated antibodies tolerated by human immune cells 

AI-generated antibodies have been tolerated by human immune cells, drug discovery company Latent Labs has announced.  The antibody designs, generated by Latent Labs’ AI platform, reportedly displayed drug-like properties, including low ex vivo immunogenicity.   Latent Labs hopes its platform, built on its Latent-X2 model, could significantly shorten… Read More

#News

#AI #Drug discovery #Electronic Lab Notebooks (ELN) #Generative AI #Large language model (LLM)

Why we need to talk about third-generation ELNs 

DDW Editor Reece Armstrong provides a sponsored interview with Rob Brown, PhD, Head of the scientific office at Sapio Sciences.  Electronic lab notebooks (ELNs) have served as essential tools in researchers’ arsenals for decades. But as technology has advanced and the demands of drug discovery and development have grown, the… Read More

#Exclusive Content

#AI #Allergen immunotherapy #Allergy #Alzheimer's #Biotech #China #Clinical trial #Eli Lilly #Obesity #Osteoarthritis #Spinogenix

This week in Drug Discovery (8 – 12 December) 

News round-up for 8 – 12 December by Bruno Quinney, Content Team at DDW.  This week in DDW, innovative treatments have been developed for neurodegenerative diseases, allergies and arthritis. Elsewhere, China is becoming the dominant force in the biotech sector.  The top stories:   … Read More

#News

Novartis head office
#AI #Drug discovery #Novartis

Relation and Novartis to advance atopic disease therapeutics 

UK biopharmaceutical company Relation has partnered with Novartis to advance therapeutics for atopic diseases.  The collaboration will pair Relation’s AI-powered drug discovery platform and human data generation capabilities with Novartis’s expertise in immuno-dermatology to identify, validate, and advance potential first-in-class targets in atopic diseases driven by immune dysregulation.  Under the terms of the agreement, Relation will… Read More

#Business & Investment #News

Chinese flag
#AI #Antibody drug conjugate (ADC) #Biotech #China #ICON

China becoming dominant force in biotech sector, survey says 

China is emerging as a ‘global innovation powerhouse’, according to clinical research organisation ICON.  ICON’s global biotech sector survey, capturing insights from more than 260 biotech professionals and venture capital executives, found that China is cementing its dominance in the sector and Western biotechs must adapt to maintain competitiveness.  According to the survey, funding remains a key challenge, with… Read More

#Business & Investment #News

#AI #Citius Pharmaceuticals #Immunotherapy

Citius Oncology prepares to launch immunotherapy treatment 

Citius Oncology has partnered with technology company Verix to advance the commercial launch of its novel immunotherapy Lymphir.  Lymphir is used for the treatment of adult patients with elapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy. The treatment was previously approved by the US… Read More

#News

Cancer cells
#AI #Cancer #Drug discovery #Immuno-oncology

One to watch: How Aulos is advancing immunotherapy cancer treatments  

DDW Editor Reece Armstrong speaks to Aron Knickerbocker, CEO of Aulos Bioscience, about the company’s efforts in the immuno-oncology field and how it is hoping to revitalise a therapeutic area that initially held promise many years ago.  The number of available treatment options for cancer patients has risen drastically since… Read More

#Exclusive Content

#AI #Clinical trial #Thermo Fisher Scientific

Thermo Fisher announces collaboration with OpenAI

Biotechnology company Thermo Fisher has announced plans to increase the impact of its growth strategy using artificial intelligence (AI) with OpenAI.  Thermo Fisher believes the collaboration with OpenAI will help to improve the speed and success of drug development, enabling customers to get medicines to patients faster and more cost… Read More

#Business & Investment #News

#AI #Antibody #Drug discovery #GPCRs

Abalone Bio talks opportunities for GPCR targets  

DDW Editor Reece Armstrong speaks to Richard Yu, CEO and Co-Founder of Abalone Bio about the company’s efforts to develop antibody antagonists for GPCR targets.  RA: What have been the biggest challenges of developing GPCR therapeutics?  RY: The number one challenge is specificity, and it plays out in a couple of… Read More

#Exclusive Content

#AI #Clinical trial

AI creating ‘measurable gains’ in clinical trials, new data reveals

Over 70% of artificial intelligence (AI) users in clinical trials see measurable gains in study speed, data analytics brand Medidata has revealed.  The findings come from a new global research report, ‘The State of AI In Clinical Trials: Today and Tomorrow’, which investigates how AI is redesigning… Read More

#News

#AI #Innovation #UK

Lord Hague of Richmond opens new £1.2 billion UK innovation district

Lord Hague of Richmond, Chancellor of the University of Oxford, has opened a flagship £1.2 billion ($1.6 billion) global innovation district in Oxford in a boost to UK science, technology and AI sectors.  Oxford North, approximately one million square feet in size, is equipped with newly developed… Read More

#News

Zika virus
#AI #SARS-CoV-2 #virus

New AI-powered database set to accelerate virus research

UK researchers have launched a new platform described as ‘the most comprehensive human virus protein database’ in the world, it has been revealed.  Viro3D, which was developed by researchers at the MRC-University of Glasgow Centre for Virus Research, uses AI to offer new perspectives on viruses, allowing… Read More

#News

#AI #Drug discovery #Financing

DaltonTx set to build AI-enabled drug discovery platforms

UK-based technology company DaltonTx has announced the completion of a £4 million ($5.4 million) financing round to build adaptive AI-enabled drug discovery platforms.  The company, which exited from stealth, is planning on building platforms giving research teams instant access to AI-enabled drug discovery, bypassing their need for… Read More

#News

Artificial intelligence
#AI #Data #Drug discovery #Merck

Merck and Siemens extend partnership for AI projects 

US pharmaceutical giant Merck and technology company Siemens have signed a new Memorandum of Understanding (MoU), extending their strategic partnership to accelerate AI and data-driven drug discovery and development.  The MoU focuses on delivering integrated software solutions, systems and consumables that harness automation, data and AI to connect drug discovery,… Read More

#Business & Investment #News

#AI #Gene editing

Revvity and Profluent collaborate on gene-editing toolkit

Revvity has announced a collaboration with biotechnology company Profluent to accelerate the development of novel gene-editing therapies.  The collaboration will bring together a range of Profluent’s novel AI-engineered enzymes with Revvity’s established Pin-point base editing platform, creating a therapeutically relevant base editing toolkit.  The new Pin-point configuration will allow for increased… Read More

#Business & Investment #News